Pharmacological and cell-specific genetic PI3Kα inhibition worsens cardiac remodeling after myocardial infarction

Chen, Xueyi; Zhabyeyev, Pavel; Azad, Abul Kalam; Vanhaesebroeck, Bart; Grueter, Chad E.; Murray, Allan G.; Kassiri, Zamaneh; Oudit, Gavin Y.

doi:10.1016/j.yjmcc.2021.04.004

“…The NFC hearts were obtained from brain dead donors with no past history of major comorbidities or cardiovascular diseases, and antemortem echocardiography demonstrated normal ejection fraction of the left and right ventricles as well as normal LV dimensions. 21 , 22 , 23 , 24 , 25 Informed consent was obtained from all patients and both programs conformed to the ethical principles of the Declaration of Helsinki, and were approved by the institutional review committee and Health Research Ethics Board at the University of Alberta, Edmonton, Canada. Clinical data were obtained by chart review.…”

Section: Methodsmentioning

confidence: 99%

“…Heart tissue procurement strictly followed our well‐established protocols. 21 , 22 , 23 , 24 , 25 Transmural myocardial samples from both ventricles were obtained by avoiding the epicardial fat and scar tissues. For this study, mid‐anterior ventricular walls from both LV (approximately two‐thirds below the aortic valves) and right ventricle (RV, approximately two‐thirds below the tricuspid valves) were procured from the NFC and DCM failing hearts, whereas peri‐infarcted and non‐infarcted regions from LV were collected from failing hearts with CAD involving the left anterior descending artery (LAD).…”

Section: Methodsmentioning

confidence: 99%

Myocardial Iron Deficiency and Mitochondrial Dysfunction in Advanced Heart Failure in Humans

Zhang

¹

,

Jamieson

²

,

Grenier

³

et al. 2022

JAHA

Self Cite

View full text Add to dashboard Cite

Background Myocardial iron deficiency (MID) in heart failure (HF) remains largely unexplored. We aim to establish defining criterion for MID, evaluate its pathophysiological role, and evaluate the applicability of monitoring it non‐invasively in human explanted hearts. Methods and Results Biventricular tissue iron levels were measured in both failing (n=138) and non‐failing control (NFC, n=46) explanted human hearts. Clinical phenotyping was complemented with comprehensive assessment of myocardial remodeling and mitochondrial functional profiles, including metabolic and oxidative stress. Myocardial iron status was further investigated by cardiac magnetic resonance imaging. Myocardial iron content in the left ventricle was lower in HF versus NFC (121.4 [88.1–150.3] versus 137.4 [109.2–165.9] μg/g dry weight), which was absent in the right ventricle. With a priori cutoff of 86.1 μg/g d.w. in left ventricle, we identified 23% of HF patients with MID (HF‐MID) associated with higher NYHA class and worsened left ventricle function. Respiratory chain and Krebs cycle enzymatic activities were suppressed and strongly correlated with depleted iron stores in HF‐MID hearts. Defenses against oxidative stress were severely impaired in association with worsened adverse remodeling in iron‐deficient hearts. Mechanistically, iron uptake pathways were impeded in HF‐MID including decreased translocation to the sarcolemma, while transmembrane fraction of ferroportin positively correlated with MID. Cardiac magnetic resonance with T2* effectively captured myocardial iron levels in failing hearts. Conclusions MID is highly prevalent in advanced human HF and exacerbates pathological remodeling in HF driven primarily by dysfunctional mitochondria and increased oxidative stress in the left ventricle. Cardiac magnetic resonance demonstrates clinical potential to non‐invasively monitor MID.

show abstract

“…PI3Kα/AKT signaling plays crucial roles in the pathological process of MI [ [71] , [72] , [73] ]. PI3Kα regulates multiple downstream pathways that control cell growth, survival, and proliferation.…”

Section: Discussionmentioning

confidence: 99%

“…PI3Kα regulates multiple downstream pathways that control cell growth, survival, and proliferation. Inhibition of PI3Kα by BYL719 worsens cardiac remodeling after MI [ 71 ]. AKT activation is required for some therapeutic approaches upon heart ischemic injury [ 72 , 73 ].…”

Section: Discussionmentioning

confidence: 99%

Fibroblast growth factor 7 alleviates myocardial infarction by improving oxidative stress via PI3Kα/AKT-mediated regulation of Nrf2 and HXK2

Mei

¹

,

Chen²,

Chen³

et al. 2022

View full text Add to dashboard Cite

“…Hence, PI3Kα/PIP3 are negative regulators of gelsolin activity. Furthermore, in experimental myocardial infarction, PI3Kα activity necessitated endothelial cell and cardiomyocytes hypertrophic response [ 51 ]. In this setting, pharmacological ablation of PI3Kα led to worsened cardiac dysfunction, profound apoptosis and inflammation, and suppressed Akt/glycogen synthase kinase 3β/endothelial nitric oxide synthetase signalling, as well as hypertrophy, post-MI [ 51 ].…”

Section: Pi3k(p110α) Mediates Atrial Size and Afmentioning

confidence: 99%

PI3K(p110α) as a determinant and gene therapy for atrial enlargement in atrial fibrillation

Ezeani

¹

,

Prabhu

²

2022

Mol Cell Biochem

6

0

View full text Add to dashboard Cite

Atrial fibrillation (AF) is an irregular heart rhythm, characterised by chaotic atrial activation, which is promoted by remodelling. Once initiated, AF can also propagate the progression of itself in the so-called ‘‘AF begets AF’’. Several lines of investigation have shown that signalling molecules, including reactive oxygen species, angiotensin II, and phosphoinositide 3-kinases (PI3Ks), in presence or absence of cardiovascular disease risk factors, stabilise and promote AF maintenance. In particular, reduced cardiac-specific PI3K activity that is not associated with oncology is cardiotoxic and increases susceptibility to AF. Atrial-specific PI3K(p110α) transgene can cause pathological atrial enlargement. Highlighting the crucial importance of the p110α protein in a clinical problem that currently challenges the professional health care practice, in over forty (40) transgenic mouse models of AF (Table1), currently existing, of which some of the models are models of human genetic disorders, including PI3K(p110α) transgenic mouse model, over 70% of them reporting atrial size showed enlarged, greater atrial size. Individuals with minimal to severely dilated atria develop AF more likely. Left atrial diameter and volume stratification are an assessment for follow-up surveillance to detect AF. Gene therapy to reduce atrial size will be associated with a reduction in AF burden. In this overview, PI3K(p110α), a master regulator of organ size, was investigated in atrial enlargement and in physiological determinants that promote AF.Table 1 Transgenic and Knockout Mouse Models of AF Gene Alteration Atrial enlargement Fibrosis Thrombus Ventricular dysfunction based on echo and/or catheter Conduction abnormalities by ECG APD Alteration AF pattern/other major cellular and molecular mechanisms References Rho GDIα TG Cardiac-specific overexpression of Rho GDP dissociation inhibitor (GDI)α with α-myosin heavy chain (α-MHC) promoter Atrial weight 0.6-fold increase vs NTg at 4 months but no changes at 4 weeks ✔ no significant increase in atrial and ventricle Not reported ↔ Sinus bradycardia, varying degrees of AV block, prolongation of P-wave duration, and PR interval at 7 months Not reported SpontaneousOther mechanismsoreduced Connexin 40 expressionoincreased expression of RhoA, Rac1, and Cdc42 [58] RhoA Cardiac-specific overexpression of RhoA with α-MHC promoter Atrial weight threefold increase vs NTg ✔ inventricle Not reported ✔ Bradycardia and AV block Not reported SpontaneousOther mechanismsoincreased expression of hypertrophic genesoInflammation [59] Junction TG Cardiac-specific overexpression of junctin protein with α-MHC promoter Atrial weight, more than tenfold increase vs WT for right atrium ✔ in atrial and ventricle ✔ in left and right atria ✔ Bradycardia Atrial and ventricle APD70,phase 3 ↑ SpontaneousOther mechanismsoreduced triadin, RYR2, diastolic Ca2+, and Ca2+ transient amplitude [60] Junctate 1 TG Cardiac-specific SR-located Ca2+-binding proteinjunctate 1 overexpression with α-MHC promoter Atrial weight, fourfold increase for left atrium and about fivefold increase for right atrium vs WT ↑ in atria and ventricle ✔ Intra-atrial thrombi ✔ Ventricular bigeminy, sinus pause, and bradycardia APD90, phase 4 ↑ SpontaneousOther mechanismsoreduced phospholamban phosphorylation, troponin I phosphorylation, Calreticulin, and RyR2 channeloreduced SR Ca2+ content, Ca2+ transient amplitudeoincreased ICa,L [61] AMPK TGN488I Cardiac-specific PRKAG2 (AMPK γ2 subunit) overexpression with missense mutation Not reported Not reported Not reported ✔ Reduced PR interval,persistent sinus bradycardia without AV block Not reported Spontaneous and paroxysmalOther mechanismsocardiac glycogen accumulation [62] A1AR TG Cardiac-specific overexpression of A1 adenosine receptor (A1AR) with α-MHC No difference No fibrosis Not reported ✔ Slow AV conduction APD90, phase 4 ↔ APD50,phase 2 ↔ APD70,phase 2 ↔ Spontaneous [63] A3tg TG Cardiac-specific overexpression of A3 adenosine receptor (A3AR) with α-MHC promoter Atrial size onefold and twofold increase at 12 weeks and 21 weeks, respectively, vs NTg Not present in atria and ventricle Not reported ✔ Absence of normal sinus rhythm, bradycardia, and intermittentlycomplete Not reported SpontaneousOther mechanismsoreduced SERCA mRNA levels [64] RTEF1 TG Cardiac-specific overexpression of Transcription enhancer factor-1-related factor(RTEF1) with α-MHC promoter Atrial weight4–sixfold increase vs control Not present in atria and ventricle ✔ Organised Not reported Slow conduction in working myocardium, prolonged PR interval, and QRS duration Not reported SpontaneousMechanismsoincreased PP1β phosphataseochronic dephosphorylation of cardiac connexin [65] ACE 8/8 TG Cardiac-restricted angiotensin-converting enzyme (ACE)Overexpression with α-MHC Ang II concentration was 4.3-fold higher in ACE mice compared to WT Atrial weight, about threefold increase vs WT ✔ in atria but not in ventricle Not reported ✔ AV block Not reported Spontaneous [66] Kir2.1 TG Kir2.1 IK1 channel subunit cardiac-specific overexpression with α-MHC promoter Atrial weight, left and right atrial to body weight 65% and 141% increase, respectively, vs control Not reported Not reported ✔ Absence of T wave and reduced QT interval APD90, phase 4 ↓APD50,phase 2 ↔ APD75,phase 3 ↔ MAP90Phase 4 ↓MAP75phase 3 ↓MAP50,phase 2 ↔ Spontaneous [67] Kcne1−/− K+-channel KCNE1 subunit global protein deletion in mouse Normal atrial size Not present in atria and ventricle Not reported ↔ AV block APD50, phase 2 ↓APD90, phase 4 ↓ Spontaneous [68] hKCNE1-hKCNQ1 TG Human (h)KCNE1-hKCNQ1 Cardiac-specific overexpression with α-MHC promoter in mouse Not reported Not reported Not reported Not reported Complex atrial and irregular ventricular excitation β-AR mediatedAPD50,phase 2 ↑APD90, phase 4 ↓ SpontaneousOther mechanismsoIncreased IKs density [69] Des−/− Desmin global knockout Not reported Not reported Not reported Not reported Supraventricular premature beats, spontaneous ventricular premature beats, and Wenckebach periodicity Not reported SpontaneousOther mechanismsoHypokalemia,oReduced refractory period [70] CREM-IbΔC-X Human cAMP-response element modulator (CREM) heart-directedoverexpression with α-MHC promoter Atrial weight, about 5–sevenfold increase vs NTg at 12–16 weeks Not present in left atrium and ventricle ✔ Organised thrombi in left and right atria ✔ Not reported Not reported SpontaneousOther mechanismsoReduced phosphorylation of CREB and of PLBoIncreased phosphorylation of SERCA2, PP1, and mRNA levels of ANP [71] CREM-IbΔC-X Human cAMP-CREM heart-directedOverexpression with α-MHC promoter Left atrial size, twofold increase vs WT at 13–17 weeks ↑ in atria Not reported Not reported Ectopic beats APD25,phase 1 ↑APD50,phase 2 ↑APD90phase 4 ↑ Spontaneous and persistentOther mechanismsoLeaky SR Ca2+ storesoDownregulation of connexin 40 [72] CREM-IbΔC-X Human cAMP- CREM and reduced RyR2-S2814A phosphorylation heart-directedoverexpression with germline transmission and Meox2-Cre crossing Atrial weight, sixfold increase vs WT at 3 months ↑ in atria and ventricle Not reported ↔ Spontaneous atrial ectopy APD80, phase 4 ↑ Spontaneous at 3-month paroxysmal and persistent at 4–5 monthsOther mechanismsoincreased SR Ca2+ leak and CaMKII activityoreduced connexin 40 [73] JDP TG Heart-restricted c-Jun dimerization protein 2 overexpression with α-MHC promoter Atrial cell diameter 1.4-fold increase vs WT Not present in the atrial and ventricle Not reported ↔ Increased PR interval, AV block andWenckebach periodicity Not reported SpontaneousOther mechanismsoreduced expression of connexin 40 and 43oAng II signalling [74] RacET Heart-restricted constitutively active Rac1 RhoGTPase overexpression with α-MHC promoter Atrial weight, fourfold increase vs WT ↑ in atria and ventricle Not reported ✔ No observable conduction defects except AF Not reported Spontaneous and persistentOther mechanismsoincreased NADPH oxidase activity [75] Anxa7−/− Annexin global knockout Not reported Not reported Not reported ↔ at basal AV block, ventricular tachyarrhythmia, shorter P-wave and QRS duration, and abnormal conduction velocity Not reported SpontaneousOther mechanismsoreduced protein expression of SERCA2aoincrease expression of NCX proteinoβ1-adrenergic signalling [76] TNF1.6 TG Heart-directedoverexpression of tumour necrosis factor-α with α-MHC promoter Isolated atrial area 3.6-fold increase from 6 to 9 months in female vs NTg ✔ in atria ✔ Organised thrombi in atria Not reported Episodes of second degree AV block, premature beats, and Ventricular ectopy APD75Phase 4 ↔ SpontaneousOther mechanismsoimpaired Ca2+ loadingoreduced intracellular Ca2+ transients [77] MHCsTNF TG Cardiac-specific overexpression of tumour necroticfactor with α-MHC promoter Not reported Not reported Not reported ✔ AV junctional rhythm, short PR interval and wide QRS complex Not reported SpontaneousOther mechanismsoreduced connexion 40 expressionoinflammation [78] MURCTG Cardiac-specific overexpression of muscle-related coiled-coil protein with α-MHC promoter Enlarged atrial compared to NTg ↑ in atria and ventricle Thrombus in the left atrial ✔ Complete AV block and prolongation of the PR interval Not reported SpontaneousOther mechanismsoreduced SERCA2, increased ANP, BNP, βMHC, TGF-β1, TGF-β2, and TGF-β3 [79] Nup155± Reducednuclear envelope permeability by nucleoporin (NUP) 155 gene missense mutation on R391H Not reported Not reported Not reported Not reported Irregular RR intervals APD90, phase 4 ↓ SpontaneousOther mechanismsoreduced HSP70 nuclear localization [80] a1D−/− L-type Ca2+ channel (Cav1.3) subunit global knockout Not reported Not reported Not reported Not reported SA andAV nodes conduction defects Not reported SpontaneousOther mechanismsolack of Cav1.3, and reduced ICa,L [81] LTCC (α1D−/−) L-type Ca2+ channel α1D subunit global knockout Smaller compared with WT Not reported Not reported Not reported Sinus bradycardia and AV block Not reported SpontaneousOther mechanismsoreduced ICa,L, Ca2+ transient amplitude, and SR Ca2+ content [82] dnPI3K-DCM Cardiac-specific dominant negative phosphoinositide 3-kinase p110α (dnPI3K) DCM due to overexpression of mammalian sterile 20-like kinase 1 expression with α-MHC promoter Atrial size 3.45-fold increase vs NTg ↑ in atriaand ventricle ✔ Chronic thrombi in the left atrium ✔ Prolonged PR intervals, double peak P-wave, and second and third degreeAV block Not reported SpontaneousOther mechanismsoaltered expression of metabolic genes and K+ channelsoreduced HSP70 [16] Dct−/− Melanin synthesisenzyme dopachrome tautomerase global knockout Not reported No Not reported ↔ No observable conduction defects except for AF APD50, phase 2 ↔ APD90, phase 4 ↔ SpontaneousOther mechanismsoplasma membrane caveolae accumulationoenlargement of mitochondria [83] RyR2R176Q/+ R176Q mutation in RYR2 gene through germline transmission and Meox2-Cre crossing Normal atrial size No fibrosis in atrial and ventricle Not reported Not reported RR interval variability, absence of P-wave APD50 phase 2 ↔ APD80 phase 4 ↔ SpontaneousOther mechanismsoincreased CaMKII-dependent phosphorylation of RyR2oelevated SR Ca2+ leak [84] Gαq TG Overexpression of activated Gαqcardiac protein with α-MHC promoter Left atrial size, 2.5-fold increase vs WT ↑ in atria but not in ventricle ✔ Left atrial, unorganised thrombus Not reported Premature atrial contraction and irregular RR interval APD80, phase 4 ↑ Spontaneous [85] NppaCre+Pitx2−/− Atrial and ventricular-restricted loss of function of paired-like homeodomain transcription factor 2 (PITX2) Atrial length about 1.6-fold increase for left atrium and 1.2-fold increase for right atrium vs WT ↑ in ventricle but not in atria Not reported Not reported AV block APD20 phase 1, ↔ APD50 phase 2, ↔ APD90 phase 4, ↔ SpontaneousOther mechanismsoreduced expression of Pitx2,oreduced expression of Nav1.5oreduced expression of Kir2.1 [86] AnkB± Ankyrin-B (ANK2) heterologous null mutation Not reported Not reported Not reported ✔ Spontaneous bradycardia and abnormal ventricular response APD90 phase 4,

show abstract

Pharmacological and cell-specific genetic PI3Kα inhibition worsens cardiac remodeling after myocardial infarction

Cited by 10 publications

References 51 publications

Myocardial Iron Deficiency and Mitochondrial Dysfunction in Advanced Heart Failure in Humans

Myocardial Iron Deficiency and Mitochondrial Dysfunction in Advanced Heart Failure in Humans

Fibroblast growth factor 7 alleviates myocardial infarction by improving oxidative stress via PI3Kα/AKT-mediated regulation of Nrf2 and HXK2

PI3K(p110α) as a determinant and gene therapy for atrial enlargement in atrial fibrillation

Contact Info

Product

Resources

About